Uteg K H, Tausendfreund K
Folia Haematol Int Mag Klin Morphol Blutforsch. 1987;114(1):153-69.
By referring initially to remarks about the structure and function of the coagulation factor VIII and about the manufacture and demand for preparations for the substitution treatment in patients affected with haemophilia A, possibilities are presented how to increase the collection of factor VIII by applying intensive measures. These involve the impact on the basic material (including donors) as well as process variables within the range of plasma collection and process technique. On the basis of own research results and data from literature the following measures can be introduced and evaluated as far as their effect on the collection of factor VIII is concerned: Donor testing, selection: increased by 25% approximately Plasmapheresis, blood bags: (prerequisite for certain technological measures) Thawing technique: increase by 20-30% approximately (thaw siphon) Citrate-free anticoagulant: increase by 30% approximately (e.g. heparin) Donor conditioning: increased by 200-400% approximately (DDAVP) The establishment of possible and reasonable combinations of measures can contribute to intensify the collection of factor VIII. The advantages to be expected are mentioned. The level of gene-technological collection of factor VIII is dealt with prospectively.
通过首先提及有关凝血因子VIII的结构和功能以及甲型血友病患者替代治疗制剂的生产和需求的论述，展示了如何通过采取强化措施来增加因子VIII的采集量。这些措施涉及对基础材料（包括献血者）的影响以及血浆采集范围内的过程变量和工艺技术。根据自身研究结果和文献数据，就其对因子VIII采集的影响而言，可引入并评估以下措施：献血者检测、选择：大约增加25%；血浆置换、血袋：（某些技术措施的前提条件）；解冻技术：大约增加20 - 30%（解冻虹吸管）；无枸橼酸盐抗凝剂：大约增加30%（如肝素）；献血者预处理：大约增加200 - 400%（去氨加压素）。建立可行且合理的措施组合有助于强化因子VIII的采集。文中提到了预期的优势。前瞻性地探讨了因子VIII基因技术采集的水平。
